Immunocore Holdings plc Current Tax Relating To Items Charged Or Credited Directly To Equity
Immunocore Holdings plc (IMCR) reported Current Tax Relating To Items Charged Or Credited Directly To Equity of GBP 0 for the 12-month period ending 2021-12-31, per its 20-F filed 2022-03-03.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:CurrentTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2022-03-03
| Period end | Current Tax Relating To Items Charged Or Credited Directly To Equity 12 month |
|---|---|
| 2021-12-31 | 0.00 GBP 20-F · filed 2022-03-03 |
| 2020-12-31 | 0.00 GBP 20-F · filed 2022-03-03 |
| 2019-12-31 | 0.00 GBP 20-F · filed 2022-03-03 |
| 2018-12-31 | 125.00K GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |